Deva Holding, restructuring and two new plant to begin production in 2008 because of the total investment has reached to $ 200 million with operational costs announced. Deva, 2009 for 350 million dollars and 500 million TL sales turnover targets.
Deva Holding's investment and to provide information about the 2009 target with the General Director Serdar Sözer held a press conference the Chairman of the Board Philpp D. Haas "2008 In a sense we have re-established as an important future years and provide the basics in a way have again. 4 new pharmaceutical production facility is put into human resources in the sense that a comprehensive restructuring performed. 2009'un in the first quarter, all these studies will be completed "he said.
- "2009 look optimistic" --
Haas, 2008 for the construction of production facilities of 100 million dollars is the direct investment costs, implementation of other operational costs of the total investment figure is closer to 200 million dollars by specifying said:
"Moving and existing machines as well as re-plant some drugs on the market can not offer period due to surface 2008, is considered to be a very successful year zor.Ancak mean a bigger picture look at the Deva's now a big leap and is ready to perform the 2009 I can say with confidence that we have looked at large. 2009 We will collect all the fruits of investment. Business in 2009, despite challenging conditions look optimistic. "
- "We have consigned SALES DIRECT SALES DROP to have the" --
At the meeting questions of press members also answering Haas, 2008'deki investments provides information about, the "Factory of the next construction costs became serious. Moving and machines of the plant cost 30 million dollars was at the level. Market this move could not give the period of medication due to loss of sales from our 20 million dollar around are calculated. Moreover, the cost of construction delays as well, around 20 million dollars. So, in addition to construction costs, this number itself on a very serious emerging and operational expenditure can also have realized, "he spoke. Sales method, and now consigned to leave in 2008 to move to direct sales methods Haas recording "consigned sales in this channel to have stopped over 10 million dollars in total sales was around a negative impact," he said.
- "We have foreseen the crisis, but did not abandon INVESTMENT" --
Haas made an assessment on the crisis said:
"Crisis were envisaged, but a surprise to me that the crisis of development was so delayed. Pharmaceutical industry from this crisis, at least affected sector. So it has made investments would not have hesitated. We take a risk and we do it right now to see it. Turkey for the pharmaceutical sector and for Deva we see a bright future. Here, a predominantly equity investment saw the benefits. In essence, our low-rate debt structure. 2008 capital increase twice gittik.2009 'from the second half of our equity investment in a structure weight will go. "
About 2009 Philipp Hasse describes the expectations, the results of the January transfer well when the "2008 period ürünsüz period of stay had a negative impact. Now, in 2009 will not effect such a sale will be fine. Also because of the production capacity could not agree on some auctions. Now effectively to the 2009 auction will take place. This effect is also visible to the sales performance, "he said.
- "Not possible to invest without GROWTH" --
Without investing in growth opportunities that the recording Haas, "We plant in Levent, and by selling our land is very true we do a job and the right have undertaken a risk. Now quickly finish the plant production capacity of the market can meet the needs we have made. Step-by-step in this process would be more difficult now is We could be. Zorlu have come to the end of the day, "he said.
Deva's current product portfolio, as well as new drugs enter areas Haas said, "We fundamentally weighted antibiotics we were a company. But two years ago, we received a decision in other areas did. Now, the product portfolio of the central nervous system, cardiovascular, gastro, such as oncology Our efforts are also expanding in areas. Antibiyotik be major player in maintaining our role primarily as growth will take place in this new drug category, "opinions were expressed.
- "Our eyes ENVIRONMENT ON" --
Haas, Are dividends to distribute "the question as," We're not against Dividend of course to distribute. However, for our investors, our goal is actually much more valuable is a company distributes dividends yaratmak.Dolayısıyla also may be a small figure "was the answer.
Haas, the world of pharmaceutical merger to a question relating to Turkey, to reflect,''All the world in many sectors as the pharmaceutical industry mergers and greater structure in the process is experiencing the emergence of the environment. Purchase a large merger Pfizer'ın Wyeth'i, but Turkey will have an impact in a short time to market, we do not think. Everything going on around us as against our eyes open. However, a future merger-Deva visible to purchase no idea "gave money.
- "EMPLOYMENT decrease in the NO" --
According to the information provided by the General Director Serdar Sözer, Deva Holding, the Turkish pharmaceutical sector with a market share of 5.2 percent in the box 5 basis, with a market share of 3.6 per cent of turnover is the basis of 8 players are in the position. Sözeri currently the total number of employees is 1800, crisis conditions have been careful to grow and a decrease in employment not planned, but because of the new plant could create new jobs, he said.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment